23.03.2016
Eckert & Ziegler Strahlen- und Medizintechnik AG DE0005659700
DGAP-News: Eckert & Ziegler 2015 Annual Financial Statements: Sales Growth of 10%. Profit Increase of 58% thanks to Extraordinary Income.
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s):
Final Results/Forecast
Eckert & Ziegler 2015 Annual Financial Statements: Sales Growth of 10%.
Profit Increase of 58% thanks to Extraordinary Income.
23.03.2016 / 07:45
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, March 23, 2016. Eckert & Ziegler Strahlen- und Medizintechnik AG
(ISIN DE0005659700), a Berlin-based company specializing in isotope
technology for medical, scientific and industrial applications, reported
sales of EUR 140.0 million in fiscal year 2015. This corresponds to an
increase of EUR 12.8 million, or 10%, on the prior year and is largely
attributable to the euro/US dollar exchange rate. Earnings per share
improved by EUR 0.75 per share to EUR 2.03 per share, which includes two
one-off effects. The disposal of the OctreoPharm Sciences GmbH (OPS)
interest had a positive impact. Higher costs for pending disposal services
weighed down on the results in Environmental Services.
The largest segment, Isotope Products, reported a EUR 7.4 million sales
increase to EUR 66.9 million thanks to currency effects. Sales in the
Radiation Therapy segment improved sharply to EUR 30.9 million following a
weak year in 2014. The segment also profited from the more favorable USD
exchange rate. Tumor irradiation equipment deliveries also increased again
due to the completion of delayed projects from the prior year, with the
launch of SagiNova(R) providing an additional boost. In the Radiopharma
segment, the equipment division saw an excellent performance. Sales in
Modular-Lab systems picked up again, triggering a simultaneous increase in
demand for consumables. Approved pharmaceutical gallium generators also
registered an improvement in sales. The cyclotron division benefited from
newly acquired products for diagnosing Alzheimer's disease. However, these
positive effects were practically neutralized by subsiding prices and
volumes for traditional FDG products. Our price increases and the expansion
of business operations at the UK interest led to a substantial improvement
in sales in the Others segment. This is exclusively attributable to
services, and was not related to the increase in provisions for disposals.
Cash flow from operating activities increased by EUR 5.6 million to EUR
16.2 million which does not include the above-mentioned one-off effects.
The reduction in receivables and inventories is largely responsible for the
improvement. These items registered a sharp increase in the prior year. The
disposal of OPS led to a considerable inflow of cash, with investment
activities generally having a positive impact. Cash outflows from financing
activities were roughly on par with the prior year. As of the reporting
date, cash and cash equivalents increased by EUR 9.6 million to a
comfortable level of EUR 31.5 million.
Stable sales of around EUR 140 million and an EBIT of roughly EUR 16
million are expected for fiscal year 2016. This should result in
consolidated profit of some EUR 9.5 million or EUR 1.80 per share. The
forecasts are based on an exchange rate of maximum USD/EUR 1.15.
The complete financial statements can be viewed under:
http://www.ezag.com/fileadmin/ezag/user-uploads/pdf/financial-reports/engl
isch/euzj15e.pdf
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with
approximately 700 employees, is one of the world's largest providers of
isotope technology for radiation therapy and nuclear medicine.
Contributing to saving lives.
For enquiries please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.de
---------------------------------------------------------------------------
23.03.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlenund Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: [email protected]
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulated Market in Frankfurt (Prime Standard), Stuttgart;
Regulated Unofficial Market in Berlin, Dusseldorf,
Hamburg, Munich
End of News DGAP News Service
---------------------------------------------------------------------------
447867 23.03.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Eckert & Ziegler Strahlen- und Medizintechnik AG ISIN: DE0005659700 können Sie bei EQS abrufen
Medtech , 565970 , EUZ , XETR:EUZ